PUBLISHER: TechNavio | PRODUCT CODE: 2109539
PUBLISHER: TechNavio | PRODUCT CODE: 2109539
Global Anti-Thrombin Iii Testing Market 2026-2030
The global anti-thrombin iii testing market is forecasted to grow by USD 99238.6 thousand during 2025-2030, accelerating at a CAGR of 4.7% during the forecast period. The report on the global anti-thrombin iii testing market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of thrombotic disorders, technological advancements in diagnostic assays, expansion of pharmaceutical research applications.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2025 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 4.5% |
| CAGR | 4.7% |
| Incremental Value | $99238.6 thousand |
Technavio's global anti-thrombin iii testing market is segmented as below:
By End-User
- Hospitals
- Laboratories
- Academic and research institutes
By Source
- Human
- Goat milk
- Others
By Product Type
- Lyophilized
- Liquid
Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Asia
- Rest of World (ROW)
- Rest of World (ROW)
This study identifies the adoption of point of care testing as one of the prime reasons driving the global anti-thrombin iii testing market growth during the next few years. Also, expansion of emerging regional healthcare infrastructure and rise of recombinant protein production technologies will lead to sizable demand in the market.
The report on the global anti-thrombin iii testing market covers the following areas:
- Global anti-thrombin iii testing market sizing
- Global anti-thrombin iii testing market forecast
- Global anti-thrombin iii testing market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global anti-thrombin iii testing market vendors that include Abcam plc, Aviva Systems Biology Corp., Bio Techne Corp., Biomatik Corp., Biomedica Diagnostics Inc., CUSABIO Technology LLC, DIAGNOSTICA STAGO SAS, Elabscience Biotechnology Inc., ELK Biotechnology Co. Ltd., F. Hoffmann La Roche Ltd., Fortress Diagnostics, Getein Biotech Inc., Helena Biosciences Europe, Monlab Test Kits, OriGene Technologies Inc., RayBiotech Life Inc., Siemens Healthineers AG, Sysmex Corp., Technoclone GmbH, Thermo Fisher Scientific Inc., Tulip Diagnostics Pvt. Ltd., Werfenlife SA. Also, the global anti-thrombin iii testing market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by End-user
- Executive Summary - Chart on Market Segmentation by Source
- Executive Summary - Chart on Market Segmentation by Product Type
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- 2.3 Factors of disruption
- 2.4 Impact of drivers and challenges
3 Market Landscape
- 3.1 Market ecosystem
- 3.2 Market characteristics
- 3.3 Value chain analysis
4 Market Sizing
- 4.1 Market definition
- 4.2 Market segment analysis
- Market segments
- 4.3 Market size 2025
- 4.4 Market outlook: Forecast for 2025-2030
5 Historic Market Size
- 5.1 Global Anti-Thrombin III Testing Market 2020 - 2024
- Historic Market Size - Data Table on Global Anti-Thrombin III Testing Market 2020 - 2024 ($ thousand)
- 5.2 End-user segment analysis 2020 - 2024
- Historic Market Size - End-user Segment 2020 - 2024 ($ thousand)
- 5.3 Source segment analysis 2020 - 2024
- Historic Market Size - Source Segment 2020 - 2024 ($ thousand)
- 5.4 Product Type segment analysis 2020 - 2024
- Historic Market Size - Product Type Segment 2020 - 2024 ($ thousand)
- 5.5 Geography segment analysis 2020 - 2024
- Historic Market Size - Geography Segment 2020 - 2024 ($ thousand)
- 5.6 Country segment analysis 2020 - 2024
- Historic Market Size - Country Segment 2020 - 2024 ($ thousand)
6 Qualitative Analysis
- 6.1 Impact of AI on Global Anti-Thrombin III Testing Market
- 6.2 Impact of geopolitical conflicts on Global Anti-Thrombin III Testing Market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
- 7.7 Market condition
8 Market Segmentation by End-user
- 8.1 Market segments
- 8.2 Comparison by End-user
- 8.3 Hospitals - Market size and forecast 2025-2030
- 8.4 Laboratories - Market size and forecast 2025-2030
- 8.5 Academic and research institutes - Market size and forecast 2025-2030
- 8.6 Market opportunity by End-user
- Market opportunity by End-user ($ thousand)
9 Market Segmentation by Source
- 9.1 Market segments
- 9.2 Comparison by Source
- 9.3 Human - Market size and forecast 2025-2030
- 9.4 Goat milk - Market size and forecast 2025-2030
- 9.5 Others - Market size and forecast 2025-2030
- 9.6 Market opportunity by Source
- Market opportunity by Source ($ thousand)
10 Market Segmentation by Product Type
- 10.1 Market segments
- 10.2 Comparison by Product Type
- 10.3 Lyophilized - Market size and forecast 2025-2030
- 10.4 Liquid - Market size and forecast 2025-2030
- 10.5 Market opportunity by Product Type
- Market opportunity by Product Type ($ thousand)
11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12.1 Geographic segmentation
- 12.2 Geographic comparison
- 12.3 North America - Market size and forecast 2025-2030
- 12.3.1 US - Market size and forecast 2025-2030
- 12.3.2 Canada - Market size and forecast 2025-2030
- 12.3.3 Mexico - Market size and forecast 2025-2030
- 12.4 Europe - Market size and forecast 2025-2030
- 12.4.1 Germany - Market size and forecast 2025-2030
- 12.4.2 UK - Market size and forecast 2025-2030
- 12.4.3 France - Market size and forecast 2025-2030
- 12.4.4 Italy - Market size and forecast 2025-2030
- 12.4.5 Spain - Market size and forecast 2025-2030
- 12.4.6 The Netherlands - Market size and forecast 2025-2030
- 12.5 Asia - Market size and forecast 2025-2030
- 12.5.1 China - Market size and forecast 2025-2030
- 12.5.2 India - Market size and forecast 2025-2030
- 12.5.3 Japan - Market size and forecast 2025-2030
- 12.5.4 South Korea - Market size and forecast 2025-2030
- 12.5.5 Thailand - Market size and forecast 2025-2030
- 12.5.6 Indonesia - Market size and forecast 2025-2030
- 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
- 12.6.1 Brazil - Market size and forecast 2025-2030
- 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
- 12.6.3 UAE - Market size and forecast 2025-2030
- 12.6.4 South Africa - Market size and forecast 2025-2030
- 12.6.5 Israel - Market size and forecast 2025-2030
- 12.6.6 Argentina - Market size and forecast 2025-2030
- 12.6.7 Turkey - Market size and forecast 2025-2030
- 12.6.8 Colombia - Market size and forecast 2025-2030
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ thousand)
- Data Tables on Market opportunity by geography ($ thousand)
13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Rising prevalence of thrombotic disorders
- Technological advancements in diagnostic assays
- Expansion of pharmaceutical research applications
- 13.2 Market challenges
- High cost of specialized testing equipment
- Stringent regulatory approval pathways
- Standardization and assay variability
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
- 13.4 Market opportunities
- Adoption of point of care testing
- Expansion of emerging regional healthcare infrastructure
- Rise of recombinant protein production technologies
14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15.1 Companies profiled
- Companies covered
- 15.2 Company ranking index
- Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 Abcam plc
- Abcam plc - Overview
- Abcam plc - Product / Service
- Abcam plc - Key offerings
- SWOT
- 15.5 Bio Techne Corp.
- Bio Techne Corp. - Overview
- Bio Techne Corp. - Business segments
- Bio Techne Corp. - Key news
- Bio Techne Corp. - Key offerings
- Bio Techne Corp. - Segment focus
- SWOT
- 15.6 DIAGNOSTICA STAGO SAS
- DIAGNOSTICA STAGO SAS - Overview
- DIAGNOSTICA STAGO SAS - Product / Service
- DIAGNOSTICA STAGO SAS - Key offerings
- SWOT
- 15.7 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Business segments
- F. Hoffmann La Roche Ltd. - Key news
- F. Hoffmann La Roche Ltd. - Key offerings
- F. Hoffmann La Roche Ltd. - Segment focus
- SWOT
- 15.8 Getein Biotech Inc.
- Getein Biotech Inc. - Overview
- Getein Biotech Inc. - Product / Service
- Getein Biotech Inc. - Key offerings
- SWOT
- 15.9 Helena Biosciences Europe
- Helena Biosciences Europe - Overview
- Helena Biosciences Europe - Product / Service
- Helena Biosciences Europe - Key offerings
- SWOT
- 15.10 Monlab Test Kits
- Monlab Test Kits - Overview
- Monlab Test Kits - Product / Service
- Monlab Test Kits - Key offerings
- SWOT
- 15.11 OriGene Technologies Inc.
- OriGene Technologies Inc. - Overview
- OriGene Technologies Inc. - Product / Service
- OriGene Technologies Inc. - Key offerings
- SWOT
- 15.12 RayBiotech Life Inc.
- RayBiotech Life Inc. - Overview
- RayBiotech Life Inc. - Product / Service
- RayBiotech Life Inc. - Key offerings
- SWOT
- 15.13 Siemens Healthineers AG
- Siemens Healthineers AG - Overview
- Siemens Healthineers AG - Business segments
- Siemens Healthineers AG - Key offerings
- Siemens Healthineers AG - Segment focus
- SWOT
- 15.14 Sysmex Corp.
- Sysmex Corp. - Overview
- Sysmex Corp. - Business segments
- Sysmex Corp. - Key news
- Sysmex Corp. - Key offerings
- Sysmex Corp. - Segment focus
- SWOT
- 15.15 Technoclone GmbH
- Technoclone GmbH - Overview
- Technoclone GmbH - Product / Service
- Technoclone GmbH - Key offerings
- SWOT
- 15.16 Thermo Fisher Scientific Inc.
- Thermo Fisher Scientific Inc. - Overview
- Thermo Fisher Scientific Inc. - Business segments
- Thermo Fisher Scientific Inc. - Key news
- Thermo Fisher Scientific Inc. - Key offerings
- Thermo Fisher Scientific Inc. - Segment focus
- SWOT
- 15.17 Tulip Diagnostics Pvt. Ltd.
- Tulip Diagnostics Pvt. Ltd. - Overview
- Tulip Diagnostics Pvt. Ltd. - Product / Service
- Tulip Diagnostics Pvt. Ltd. - Key offerings
- SWOT
- 15.18 Werfenlife SA
- Werfenlife SA - Overview
- Werfenlife SA - Product / Service
- Werfenlife SA - Key offerings
- SWOT
16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- Research methodology
- 16.5 Data procurement
- Information sources
- 16.6 Data validation
- Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
- List of abbreviations
